Provided by Tiger Trade Technology Pte. Ltd.

Elicio Therapeutics

3.04
-0.0350-1.14%
Pre-market: 3.100.0600+1.97%07:31 EDT
Volume:279.27K
Turnover:855.97K
Market Cap:79.90M
PE:-1.40
High:3.11
Open:3.11
Low:3.03
Close:3.08
52wk High:16.00
52wk Low:2.66
Shares:26.28M
Float Shares:19.19M
Volume Ratio:0.93
T/O Rate:1.46%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-2.1721
EPS(LYR):-2.5842
ROE:-774.56%
ROA:-77.88%
PB:10.07
PE(LYR):-1.18

Loading ...

Elicio shares tumble after pancreatic cancer therapy misses mid-stage study goal

Reuters
·
Jun 15

Elicio selloff brings attractive entry point, says H.C. Wainwright

TIPRANKS
·
Jun 15

Elicio Unveils Phase 2 ELI-002 Results and Phase 3 Plan

TIPRANKS
·
Jun 15

Elicio Therapeutics Is Maintained at Buy by HC Wainwright & Co.

Dow Jones
·
Jun 15

Elicio Therapeutics Shares Fall After Missing Primary Endpoint in Pancreatic Cancer Trial

MT Newswires Live
·
Jun 15

Elicio Therapeutics, Inc. : H.c. Wainwright Raises Target Price to $23 From $17

THOMSON REUTERS
·
Jun 15

Elicio Therapeutics Shares Fall 50% Premarket After Co Reports Mid-Stage Data for Its Experimental Pancreatic Cancer Therapy

THOMSON REUTERS
·
Jun 15

BUZZ-Elicio Therapeutics tumbles as pancreatic cancer vaccine misses main goal of trial

Reuters
·
Jun 15

Elicio says Phase 2 AMPLIFY-7P trial of ELI-002 7P misses primary DFS endpoint in adjuvant pancreatic cancer

Reuters
·
Jun 15

Elicio Therapeutics - Eli-2 7P Demonstrates Favorable Safety and Tolerability Profile

THOMSON REUTERS
·
Jun 15

Elicio Therapeutics Reports Results From Phase 2 Amplify-7P Study and Outlines Refined Phase 3 Development Strategy for Eli-002 7P in Adjuvant Pancreatic Cancer

THOMSON REUTERS
·
Jun 15

Elicio Therapeutics - Evaluating Strategic Financing and Partnering Opportunities

THOMSON REUTERS
·
Jun 15

Elicio Therapeutics - to Focus Phase 3 Development on R0 Resected Population With Additional Eli-2 7P Dosing

THOMSON REUTERS
·
Jun 15

Elicio Therapeutics - Amplify-7P Phase 2 Study Does Not Meet Primary Dfs Endpoint in Intent-to-Treat Population

THOMSON REUTERS
·
Jun 15

U.S. RESEARCH ROUNDUP-Ferrari, Hawkeye 360, Micron Technology

Reuters
·
Jun 15

Elicio Therapeutics Initiated at Buy by B. Riley Securities

Dow Jones
·
Jun 11

U.S. RESEARCH ROUNDUP- Datadog, Eli Lilly, Oracle

Reuters
·
Jun 10

Elicio Therapeutics Inc : B. Riley Initiates Coverage With Buy Rating; Target Price $27

THOMSON REUTERS
·
Jun 10

Elicio Therapeutics publishes data on AMP-DNA adjuvant technology

TIPRANKS
·
Jun 01

Elicio Therapeutics reports preclinical AMP-DNA adjuvant study in Science Advances showing durable T-cell responses

Reuters
·
Jun 01